期刊
FOOD AND CHEMICAL TOXICOLOGY
卷 48, 期 7, 页码 1836-1845出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.fct.2010.04.016
关键词
Casein hydrolysate; RYLGY and AYFYPEL antihypertensive peptides; Safety evaluation
资金
- Comunidad de Madrid and the Ministerio de Educacion y Ciencia [S-0505/AGR/0153, AGL2006-02031/ALL S2009/AGR-1469]
The Lowpep (R) is a powdered casein hydrolysate containing the antihypertensive peptides RYLGY and AYFYPEL. two sequences that correspond to alpha(s1)-casein f (90-94) (RYLGY)(1) and alpha(s1)-casein f (143-149) (AYFYPEL)(1). To support the safety, Lowpep (R) has been examined in an acute and in a 4-week repeated dose oral toxicity studies in rats. Powdered casein hydrolysate administered in a single oral gavage dose of 2000 mg/kg resulted in no adverse events or mortality. Also, casein hydrolysate administered as a daily dose of 1000 mg/kg for 4 weeks by gavage resulted in no adverse events or mortality. No evidence or treatment-related toxicity was detected during both studies. Data analysis of body weight gain, food consumption, clinical observations, blood biochemical, haematology, organ weight ratios and histopathological findings did not show significant differences between control and treated groups. It is concluded that the casein hydrolysate containing the peptides RYLGY and AYFYPEL orally administered to rats was safe and that not treatment-related toxicity was detected even at the highest doses investigated in both acute (2000 mg/kg of body weight) and repeated dose (4 weeks) oral (1000 mg/kg of body weight) toxicity studies. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据